Cost-effectiveness of Photodynamic Therapy in Early Stage Lung Cancer
Author Information
Author(s): HARUBUMI KATO, TETSUYA OKUNAKA, TAKAAKI TSUCHIDA, HIROSHI SHIBUYA, SHIRO FUJINO, KYOKO OGAWA
Primary Institution: Tokyo Medical University
Hypothesis
Is photodynamic therapy (PDT) more cost-effective than lobectomy for early stage lung cancer?
Conclusion
Photodynamic therapy (PDT) is more cost-effective than lobectomy for early stage lung cancer.
Supporting Evidence
- The total cost for the PDT group was significantly lower than that for the operated group.
- The cost-effectiveness rate for the PDT group was 30,003 yen per postoperative living month.
- The 5-year survival rate for the PDT group was 95.1%, compared to 91% for the operated group.
- PDT cases with lesions under 2 cm had a 100% 5-year survival rate.
- Quality of life remained at 100% for the PDT group, while it decreased by 10% for the operated group.
Takeaway
This study shows that using a special light treatment called photodynamic therapy is cheaper and just as effective as surgery for some early lung cancer patients.
Methodology
A cost-effectiveness analysis comparing photodynamic therapy and lobectomy based on costs and quality adjusted life years (QALYs).
Limitations
The study did not include costs after discharge and excluded treatment for accompanying diseases.
Participant Demographics
Patients with early stage lung cancer, including those with lesions smaller than 2 cm.
Want to read the original?
Access the complete publication on the publisher's website